The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Third interim analysis from VIsion: ibrutinib/venetoclax in R/R CLL
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, discusses the third interim analysis from the phase II VIsion / HO141 trial (NCT03226301). The aim of the trial is to evaluate if combination treatment with venetoclax and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia can lead to MRD-guided treatment cessation and reinitiation. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
